Effect of Cyclosporine on Left Ventricular Remodeling After Reperfused Myocardial Infarction

Mewton, Nathan; Croisille, Pierre; Gahide, G.; Rioufol, Gilles; Bonnefoy, Éric; Sanchez, Ingrid; Cung, Thien Tri; Sportouch, Catherine; Angoulvant, Denis; Finet, Gérard; André‐Fouët, Xavier; Dérumeaux, Geneviève; Piot, Christophe; Vernhet, Hélène; Revel, D.; Ovize, Michel

doi:10.1016/j.jacc.2009.10.052

Cited by 177 publications

(126 citation statements)

References 17 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Importantly, our data were in agreement with those reported by Piot et al, 5 who carried out a well-designed pilot study of CsA in patients with ST-segment elevation AMI, and demonstrated smaller infarct sizes after percutaneous coronary intervention, which was confirmed by DE-MRI. Mewton et al 21 recently confirmed that CsA-induced reduction in infarct size was associated with a lower left ventricle dilatation at day 5, which was maintained at 6 months.…”

mentioning

confidence: 84%

Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model

Yin

Zhang

Wang

et al. 2013

IJN

View full text Add to dashboard Cite

Treatment of myocardial infarction (MI) with adipose-derived stem cells (ASCs) has produced promising results. Cyclosporine A (CsA) inhibits apoptosis by preventing the opening of mitochondrial permeability transition pores. A CsA nanoparticle emulsion (CsA-NP) has lower toxicity and higher efficiency as compared to CsA. In this study, we hypothesized that a combination of ASCs and CsA-NP would enhance the therapeutic efficiency in a swine MI model. MI was induced in pig hearts by occlusion of the left anterior descending artery. The animals that survived MI were divided into four groups and 1 week later received intracoronary ASCs (ASCs, n=6), intracoronary culture media in combination with CsA-NP (CsA-NP, n=6), intracoronary ASCs in combination with CsA-NP (ASCs + CsA-NP, n=6), or remained untreated (control, n=4). Animals were sacrificed 8 weeks later and were evaluated for cardiac function by delayed-enhanced magnetic resonance imaging and immunohistopathology. We observed that the left ventricular ejection fraction (LVEF) was significantly increased in the ASCs + CsA-NP group, compared to the CsA-NP group (53.6%±2.4% versus 48.6%±1.5%, P <0.05), and the ASCs group (53.6%±2.4% versus 48.3%±1.8%, P <0.05). More importantly, the infarct size was significantly smaller in the ASCs + CsA-NP group as compared to the CsA-NP group (6.2±1.7 cm 3 versus 9.1±3.4 cm 3 , P <0.05) and the ASCs group (6.2±1.7 cm 3 versus 7.5±0.6 cm 3 , P <0.05). These findings were further confirmed by analysis of the expression of cardiomyocyte markers, myosin heavy chain (α-actinin) and troponin T. In addition, the CsA-NP + ASCs treatment promoted neovascularization ( P <0.05) and inhibited cardiomyocyte apoptosis ( P <0.01) compared to the control group. This study demonstrates that CsA-NP enhanced the therapeutic benefits of ASCs transplantation for MI.

show abstract

mentioning

confidence: 84%

Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model

Yin

Zhang

Wang

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…A total of 5 RCTs, which had been published in peer-reviewed journals, were included in our studies [19][20][21][22][23][24]. We extracted the baseline study details from all the selected trials (Tables 2, 3); outcomes not included in the analysis are listed in Table 4.…”

Section: Methodsmentioning

confidence: 99%

Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

Background: Reperfusion injury is an important limiting factor associated with revascularization in acute myocardial infarction (AMI (OR 1.05,. Similarly, we did not find any significant differences in terms of cardiogenic shock, recurrent ischemia and myocardial infarction, heart failure and echocardiographic outcomes. Conclusions: Cyclosporine A is not helpful in preventing reperfusion injury in AMI. (Cardiol J 2017; 24, 1: 43-50)

show abstract

“…In a subgroup analysis, a similar reduction in infarct size was demonstrated on day 5 with cardiac magnetic resonance imaging (CMR). In a follow-up study, Mewton et al [78] found that this infarct-sparing effect of cyclosporine was persistent at 6 mo. However, in a more recent study, no effect was shown of early cyclosporine administration as an adjunct to thrombolysis in STEMI patients in relation to infarct size, left ventricular function, heart failure or death [65] .…”

Section: Pharmacological Conditioningmentioning

confidence: 97%

Novel adjunctive treatments of myocardial infarction

Schmidt

Pryds

Bøtker

2014

WJC

View full text Add to dashboard Cite

Myocardial infarction is a major cause of death and disability worldwide and myocardial infarct size is a major determinant of prognosis. Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome, but reperfusion may induce further myocardial damage itself. Development of adjunctive therapies to limit myocardial reperfusion injury beyond opening of the coronary artery gains increasing attention. A vast number of experimental studies have shown cardioprotective effects of ischemic and pharmacological conditioning, but despite decades of research, the translation into clinical effects has been challenging. Recently published clinical studies, however, prompt optimism as novel techniques allow for improved clinical applicability. Cyclosporine A, the GLP-1 analogue exenatide and rapid cooling by endovascular infusion of cold saline all reduce infarct size and may confer clinical benefit for patients admitted with acute myocardial infarcts. Equally promising, three follow-up studies of the effect of remote ischemic conditioning (RIC) show clinical prognostic benefit in patients undergoing coronary surgery and percutaneous coronary intervention. The discovery that RIC can be performed noninvasively using a blood pressure cuff on the upper arm to induce brief episodes of limb ischemia and reperfusion has facilitated the translation of RIC into the clinical arena. This review focus on novel advances in adjunctive therapies in relation to acute and elective coronary procedures.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Myocardial infarction; Primary percutaneous intervention; Coronary artery by-pass graft; Ischemiareperfusion injury; Ischemic preconditioning; Remote ischemic conditioning; Cyclosporine; Cooling; Exenatide Core tip: Patients with ischemic heart disease have a high risk of developing myocardial infarction, which is associated with considerable morbidity and mortality. Limiting the detrimental consequences of myocardial infarction is a major focus of cardiovascular research. Recent clinical studies suggest that novel adjunctive therapy with pharmacological and ischemic conditioning reduce ischemia-reperfusion injury in patients during coronary procedures. In three independent randomized trials, remote ischemic conditioning (RIC) improves clinical outcome in patients undergoing acute or elective percutaneous intervention or coronary artery bypass surgery. RIC can be performed safely and noninvasively by intermittent inflation of a blood-pressure cuff on the upper arm and is easily applicable in most clinical settings. worldwide [1,2] . Since 1990, more people have died from coronary artery disease than any other death cause [3,4] . In China, a staggering 230 million are estimated to suffer from cardiovascular disease, and three million Chinese die of cardiovascular disease annually, accounting for 41% of all deaths [5,6] . In the United States alone, cardiov...

show abstract

Effect of Cyclosporine on Left Ventricular Remodeling After Reperfused Myocardial Infarction

Cited by 177 publications

References 17 publications

Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model

Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model

Impact of cyclosporine A use in the prevention of reperfusion injury in acute myocardial infarction: A meta-analysis

Novel adjunctive treatments of myocardial infarction

Contact Info

Product

Resources

About